Analysis

Please join me at 2016 Armada Specialty Pharmacy Summit, which will take place on May 2-6, 2016, at the wonderful Wynn & Encore Las Vegas.

Based on personal experience, I can tell you that the Summit attracts an impressive diversity of pharmacies, manufacturers, health plans, wholesalers, hospital systems, pharmacy benefit managers, patient advocacy groups, and others. View the agenda and check out the list of speakers.

Below, watch a fun video review of last year's Summit. You can read my review of the 2015 summit in Specialty Pharmacy’s Bright but Complex Future: Seven Reflections on #Armada15.

Read on for more details about this great specialty pharmacy event, or just register now. See you in Vegas!

A MESSAGE FROM ARMADA HEALTH CARE

Join thousands of industry stakeholders who will be attending the upcoming 2016 Armada Specialty Pharmacy Summit in Las Vegas. Don’t Miss the Nation’s Largest Specialty Pharmacy Conference!

The Armada Specialty Pharmacy Summit returns to Wynn & Encore Las Vegas on May 2-6, 2016. This annual event is the largest U.S. healthcare conference focused on specialty pharmacy. It welcomes a blended mix of executives and professionals from a variety of pharmacy providers, pharma/biotech manufacturers, payers, drug wholesalers and other healthcare organizations.

During the four-day conference, participants will gain an in-depth understanding of all aspects of specialty pharmacy from renowned industry speakers. Over 100 hours of seminars, educational sessions and business workshops are scheduled (including more than 14 live CE credits for pharmacists). Additional agenda items include celebrity keynote speakers at the general session, vendor exhibits, expert panel discussions, networking receptions and other high-energy events.

Hotel rooms at Wynn and Encore are limited. Registration is a click away. Join thousands of industry stakeholders and confirm your participation today!

Please enjoy this video. Click here if you can’t see it.

---

The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

Yesterday, McKesson announced its acquisition of two significant oncology businesses: Vantage Oncology and Biologics. Click here to read the press release.

McKesson provided only general statements about its motivations behind the $1.2 billion deals. Fear not, dear reader. Below, I offer two key hypotheses about McKesson’s strategic considerations in purchasing the Biologics specialty pharmacy.

This much is certain: For manufacturers, the deals further illustrate the emergence of organized customers that cross traditional commercial and channel boundaries.

Brrr. This winter has felt like February since December. But winter is almost over. To celebrate and stay warm, please enjoy this month's hand-picked selection of noteworthy Drug Channels news stories. In this issue:

• Learn about WBA’s Stefano Pessina and the behind-the-scenes details of his Walgreens takeover

• Watch Pessina hype vertical integration

• Hear Express Scripts talk tough about Valeant (and wonder if it's just talk)

Plus, an exclusive report from a CVS Health cashier during cold and cough season.

P.S. For daily updates on news and articles that I think are cool and/or interesting, join the more than 2,500 people who follow @DrugChannels on Twitter.

According to new data that Apexus has made available to Drug Channels, discounted purchases made under the 340B Drug Pricing Program hit $12 billion in 2015. That’s a whopping 67% higher than the 2013 figure. I estimate that the undiscounted value of these purchases exceeds $17 billion.

Most 340B purchases are made by hospitals. My exclusive number-crunching below reveals that hospitals now receive 340B discounts on more than 44% of their drug purchases. As I predicted two years ago, the 340B program is taking over the hospital market.

How much of this money goes to uninsured and needy patients? No one knows, and the hospitals aren’t saying much. The Health Resources and Services Administration (HRSA) expects to finalize its Omnibus Guidance in the fall. Unfortunately, HRSA doesn’t seem keen on requiring that any financial savings be directed to the neediest patients. Maybe it just doesn’t want to get a blister on its little finger.

Today’s guest post comes from Michael Deninger, a pharmacy owner in Iowa who writes The Thriving Pharmacist blog. Preferred and limited networks have become a prominent feature of pharmacy benefit plans. Mike provides a fascinating, first-person perspective on this crucial trend by describing his experience living with the pros and cons of preferred pharmacy networks.

Given the importance of narrow networks, I devote all of Chapter 7 of my new 2016 Economic Report on Retail, Mail, and Specialty Pharmacies to an analysis of the trends and its impact on pharmacies, payers, and manufacturers.

As I see it, many interrelated factors support the continued adoption of narrow networks. Mike’s views complement the broader industry economics in my report and highlight why pharmacy owners generally dislike narrow networks. Let me know what you think in the comments below.

As low-cost generics come to dominate retail dispensing activity, clinics have emerged as a way for drugstores and other retail pharmacy outlets to diversify into non-dispensing revenues.

There are now about 2,000 retail clinics. Below, I examine the chains with the biggest market share: CVS Health, HEB, Kroger, Rite Aid, Target, Walgreens, and Walmart.

In 2015, the number of clinics grew slowly. In 2016, I project another year of slow growth as the big players retrench. While clinics sound like an exciting strategy, revenues from in-store clinics are—and will likely remain—a very small share of pharmacy chains’ prescription revenues.

CBI’s Formulary, Co-Pay and Access Summit
April 5-6, 2016 | Philadelphia, PA
www.cbinet.com/formulary

From the company that brought you the Coupon and Co-Pay Off-Set Strategies Series, CBI’s Formulary, Co-Pay and Access Summit provides a forum for industry to learn how to strategically navigate new access challenges, such as formulary exclusions, high deductible plans, NDC blocks and step therapy programs, while still providing valuable patient services and support, including coupons, co-pays or bridge programs.

Stakeholders providing expert insight include representatives from Acorda Therapeutics, Bayer, Biogen, Celldex Therapeutics, eMAX Health, Insys Therapeutics, Janssen, Novo Nordisk, Pfizer, PSKW and TrialCard.

Don’t miss this timely meeting designed to provide critical insights and solutions to the biggest obstacles in patient access and offer design.

For more information, please download the complete agenda or visit www.cbinet.com/formulary. Drug Channels readers will save $200 off of the standard registration rate when they use code DYQ363.*

*Cannot be combined with other offers or used towards a current registration. Cannot be combined with special category rates. Other restrictions may apply.

---

The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

Today’s guest post comes from George Kitchens, president of Artia Solutions, on behalf of Elsevier.

George provides another view on the Average Manufacturer Price (AMP) final rule from the Centers for Medicare & Medicaid Services (CMS). He describes different cost-based price estimation approaches and proposes Predictive Acquisition Cost (PAC) as an alternative way to calculate a pharmacy’s drug acquisition cost.

Click here to download Elsevier's free case study that describes how Oklahoma’s state Medicaid program used PAC to reduce generic price spending while maintaining a satisfied pharmacy network.

Is the generic drug inflation story over?

The Food and Drug Administration (FDA) is finally starting to clear the backlog of new generic drug applications. And right on cue, wholesaler executives have confirmed that generic inflation is slowing down or ending, reducing their profits.

As I told NPR’s Marketplace radio show: “The real solution is the solution that always works, which is introduce more competition in the market.” The lesson: Every so often, economics gets it right.

In Seven Pharmacy and Channel Implications of the New AMP Final Rule, I gave you my $0.02 on the Average Manufacturer Price (AMP) final rule from the Centers for Medicare & Medicaid Services (CMS).

Want to know more? Below, I highlight six useful reviews and articles about the rule.

I also provide info on two official (and free) CMS webinars happening later this week:

• For manufacturers on Wednesday, Feb. 10

• For pharmacies on Thursday, Feb. 11

Hope you enjoy this extra dose of disampbiguation!